pneumoniae isolates collected at 119 centers in year 6 of PROTEKT
US, 2,381 (35.
2%) was higher than the PROTEKT
US study result (8.
A key finding in PROTEKT
was that telithromycin was highly active against S.
US (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin in the United States) was established in 2000 to monitor antimicrobial resistance among respiratory tract pathogens across the United States.
Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT
As of June 2001, in the PROTEKT
study, 7,544 isolates of S.
A number of industry-sponsored global surveillance studies, such as the Alexander Project (GlaxoSmithKline) and PROTEKT
(Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) (sanofi-aventis), have been designed to define and monitor the prevalence and distribution of antimicrobial resistance among respiratory pathogens, detect new patterns of resistance, provide early warning of emerging resistance, and evaluate the effects of interventions aimed at reducing antimicrobial resistance.
This need for monitoring has led to the development of the PROTEKT
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000 2001 PROTEKT
Streptococcus pneumoniae isolates (N = 31,001) were collected from patients with community-acquired respiratory tract infections during the PROTEKT
US surveillance study (2000-2003).
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT
antimicrobial surveillance programme during 1999-2000.
pneumoniae have been identified (84) in over 10,000 pneumococcal isolates screened by the PROTEKT